Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs

Aaron S. Devanathan, Jason R. Pirone, Ramesh Akkina, Leila Remling-Mulder, Paul Luciw, Lourdes Adamson, J. Victor Garcia, Martina Kovarova, Nicole R. White, Amanda P. Schauer, Kimberly Blake, Craig Sykes, Erin M. Burgunder, Nithya Srinivas, Elias P. Rosen, Angela D. M. Kashuba
Aaron S. Devanathan
aUniversity of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aaron S. Devanathan
Jason R. Pirone
aUniversity of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramesh Akkina
bColorado State University, Fort Collins, Colorado, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leila Remling-Mulder
bColorado State University, Fort Collins, Colorado, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Luciw
cUniversity of California, Davis, Davis, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lourdes Adamson
cUniversity of California, Davis, Davis, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Victor Garcia
dUniversity of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martina Kovarova
dUniversity of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole R. White
aUniversity of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda P. Schauer
aUniversity of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly Blake
aUniversity of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Sykes
aUniversity of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin M. Burgunder
aUniversity of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nithya Srinivas
aUniversity of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elias P. Rosen
aUniversity of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela D. M. Kashuba
aUniversity of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA
dUniversity of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01639-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

For HIV cure strategies like “kick and kill” to succeed, antiretroviral (ARV) drugs must reach effective concentrations in putative viral reservoirs. We characterize penetration of six ARVs in three preclinical animal models and humans. We found that standard dosing strategies in preclinical species closely mimicked tissue concentrations in humans for some, but not all, ARVs. These results have implications for interpreting HIV treatment, prevention, or cure interventions between preclinical and clinical models.

TEXT

Despite 3 decades of improvements in antiretroviral (ARV) therapy, HIV eradication remains elusive. It has been postulated that inadequate ARV penetration into tissues may create pharmacological sanctuaries where HIV continues to replicate (1, 2). For instance, in lymphoid tissues, Fletcher et al. (1) suggested that ARVs do not achieve suppressive concentrations. In cerebrospinal fluid, although the ARV efavirenz (EFV) achieves concentrations at 0.5% of plasma concentrations, this still exceeds the 50% inhibitory concentration for wild-type HIV (3). Because of these tissue penetration and activity differences, a comprehensive analysis is warranted. Because some tissues are impractical to sample from humans, animal models are commonly used in HIV investigations, with standard ARV dosing strategies selected to match human blood plasma exposure. Here, we describe the tissue penetration of six ARVs in two humanized mouse models (hu-HSC [also called RAG-hu in the literature] and bone marrow-liver-thymus [BLT]), nonhuman primates (NHPs), and HIV+ humans. The hu-HSC mice are engrafted with hu-HSC, whereas BLT mice are engrafted with HSC and thymus (4).

The hu-HSC and BLT mice and NHPs were administered standard ARV doses and combinations taken from previously published treatment regimens, and this is summarized in Fig. S1 in the supplemental material (5–12). Tissues harvested from HIV+ patients an estimated 8 to 47 h postdose were obtained from the National NeuroAIDS Tissue Consortium, National Neurological AIDS Bank, and National Research Disease Interchange. Human female genital tract (FGT) and colorectal concentrations were obtained from a clinical trial (NCT01330199). Eight tissue types were examined: brain (median combined concentration of frontal cortex, cerebellum, basal ganglia, and parietal cortex), lymph node (median combined concentration of axillary, iliac, inguinal, and mesenteric lymph nodes), spleen, ileum, rectum, testes, and FGT (median combined concentration of cervix and vagina).

Tissue and plasma concentrations were quantified for (i) the administered ARVs emtricitabine (FTC), tenofovir (TFV), EFV, raltegravir (RAL), maraviroc (MVC), and atazanavir (ATV) (5–7, 10); (ii) the two active metabolites tenofovir diphosphate (TFVdp) and emtricitabine triphosphate (FTCtp) (13); and (iii) two endogenous nucleotides (dATP and dCTP). Concentrations were converted from nanogram per milliliter to nanogram per gram using a tissue density of 1.06 g/ml. Where measurements of ARV concentrations were below the limit of quantification, we imputed a value of one-half of the lower limit of quantification. Metabolite-to-endogenous nucleotide ratios (active metabolite/tissue endogenous nucleotide concentration) for each tissue were analyzed via the Wilcoxon rank-sum test with the Benjamini Hochberg P value adjustment procedure. Spearman’s rank correlation coefficients were calculated to illustrate the relationships between plasma and tissue concentrations. All analyses were performed using R 3.5.3 (Vienna, Austria).

Comparisons of ARV concentrations across multiple tissues and multiple species are shown in a rank plot in Fig. 1A, where data are grouped by species/model. Median tissue concentrations were ranked from lowest to highest. For all species and ARVs, concentrations were highest in the gastrointestinal tract (GIT; either ileum or rectum). In tissues where exposure to an ARV could be compared in at least two different species, the lowest ARV concentrations were observed mostly in hu-HSCs (18 out of 36 paired tissue-ARV measurements). Notable exceptions were found in lymph node, spleen, and FGT, where the lowest concentrations for the nucleoside reverse transcriptase inhibitors (NRTIs) FTC and TFV were measured in humans. When normalizing to plasma, the trends seen in each species for the tissue concentration rank plot were seen in the normalized-concentrations rank plot (Fig. 1B).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Rank plots of median tissue concentrations (A) and median ratios of tissue-to-plasma concentrations (B). Antiretroviral abbreviations: ATV, atazanavir; EFV, efavirenz; FTC, emtricitabine; MVC, maraviroc; RAL, raltegravir; TFV, tenofovir. Tissue abbreviations: B, brain; F, female genital tract; I, ileum; L, lymph node; R, rectum; S, spleen; T, testes. NHP, nonhuman primate. BLT mice were not dosed with EFV due to toxicity concerns. Testes were only evaluated in NHPs.

Correlation plots of ARV concentrations in tissue versus plasma were used to evaluate the proclivity of ARVs to penetrate into tissues and are shown in Fig. 2, and individual Spearman’s rank correlation coefficients are shown in Table 1. These plots and coefficients illustrate two things. First, generally, as plasma concentrations increased, the tissue concentrations increased. Across most species, the plots suggested that increasing the NRTI dose would result in increased tissue penetration in lymph node and spleen. This was confirmed numerically by the correlation coefficients. Second, less-clear trends were seen in ATV correlation plots, which indicated insignificant correlations (increased plasma concentrations did not correlate with increased tissue concentrations) consistently for NHPs and RAL correlation plots, which were inconsistent among species but were generally negative in NHPs and hu-HSC mice.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Correlation plots of tissue versus plasma concentrations across all tissues for the six antiretrovirals. Antiretroviral abbreviations: ATV, atazanavir; EFV, efavirenz; FTC, emtricitabine; MVC, maraviroc; RAL, raltegravir; TFV, tenofovir. FGT, female genital tract; NHP, nonhuman primate. BLT mice were not dosed with EFV due to toxicity concerns. Testes were only evaluated in NHPs.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

Correlation coefficients of plasma and tissue concentrations for 6 antiretrovirals

Because the efficacy of the active NRTI metabolite competes with the endogenous nucleotide it replaces during the reverse transcription process (14), we calculated the ratios of intracellular active metabolite to endogenous nucleotide concentrations against 90% effective concentration cutoffs derived from CD4+ T cells by Cottrell et al. (13). As seen in Fig. 3, FTCtp/dCTP ratios in mouse models in the lymphoid organs were not significantly different from those in humans. TFVdp/dATP ratios were similar in mouse models and humans except for spleen and FGT. Ratios in NHPs were similar to, or higher than, those in humans. In lymph node, spleen, and FGT, TFVdp/dATP ratios were significantly higher (up to 161-fold) in NHPs than in humans, despite similar plasma concentrations between the two species; in the rectum, 1.9- to 105-fold-higher ratios were noted in NHPs than in humans for both NRTIs.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

Metabolite-to-endogenous nucleotide ratio boxplots across eight tissues for FTCtp (A) and TFVdp (B). Dotted lines represent literature-derived 90% effective concentrations. NHP, nonhuman primate; BLQ, below limit of quantification; N/A, not applicable; FGT, female genital tract; FTCtp, emtricitabine triphosphate; TFVdp, tenofovir diphosphate. Testes were only evaluated in NHPs. *, P < 0.05 via Wilcoxon rank-sum test with Benjamini Hochberg P value adjustment procedure.

To our knowledge, this is the first analysis of ARV tissue penetration across multiple HIV putative reservoirs in multiple species using standard dosing strategies (8, 10, 12). Based on the correlation plots and coefficient values, we found that current ARV doses in NHPs mimic human plasma and tissue exposure, whereas mice generally have lower and more inconsistent penetration across tissues. This suggests similar tissue penetration processes for most ARVs between NHPs and humans. Our results have several important implications. First, we have shown significant heterogeneity in ARV penetration between tissues (e.g., concentrations across species in lymph nodes were 7-fold lower than in the rectum), underscoring crucial pharmacological differences between tissues. Second, we noted heterogeneity between species (e.g., TFVdp concentrations were higher in NHP FGT and mouse and NHP rectums than in the respective human tissues, despite TFV concentrations in NHPs being ∼2-fold higher than in mouse models) with standard dosing protocols. This suggests that TFV concentrations may overpredict efficacy in mice and NHPs versus humans. Third, we noted that inconsistent relationships between plasma and tissue concentrations exist with RAL, whereas a positive linear relationship exists for NRTIs in the secondary lymphoid organs, which underlines not only the heterogeneity of ARV penetration among tissues but also the importance of the secondary lymphoid organs as reservoirs (15, 16). Fourth, we noted that NHPs achieve higher metabolite/nucleotide ratios than mouse models and humans in the secondary lymphoid organs and in the FGT, and the ratios for NHPs are higher than those seen in humans in the GIT. Taken together, we discovered important differences that should be considered when translating from preclinical species to humans.

Biochemical and physiological differences related to absorption and elimination between preclinical models and humans can result in additional variability in plasma concentrations and, consequently, tissue concentrations (17, 18). Figures 2 and 3 represent tissue concentrations normalized to accompanying plasma concentrations, thereby providing a visualization of penetration into respective tissues by species at one point in time.

The current analysis has several limitations. Liquid chromatography-tandem mass spectrometry analysis of tissue homogenates provides an average concentration within tissues. We previously reported that spatial information can be gleaned from infrared matrix-assisted laser desorption electrospray ionization imaging analyses of sanctuary site tissue slices (6, 19–21). This work is ongoing. This analysis also focused on total-drug concentrations rather than protein-unbound concentrations, although NRTIs demonstrate low protein binding potential. Because the unbound ARV concentrations are responsible for pharmacological effects, it is important to compare these differences in the future. As of this writing, the tissue protein binding potential for EFV, RAL, MVC, and ATV has been measured in the brain of NHPs (6), suggesting lower protein binding in tissues than in plasma in all species.

Because ARVs are substrates for drug transporters, particularly the solute carrier and ATP-binding cassette transporter superfamilies, their tissue concentrations may be modulated by transporter activity (22). Although the current analysis did not examine the influence of drug transporters, our group has found that transporter RNA or protein tissue concentrations alone do not accurately correlate with ARV concentrations in gut-associated lymphoid tissue (5) and lymph node (7). Physicochemical properties of ARVs, such as lipophilicity and pH trapping, may contribute to tissue drug concentration. For instance, EFV has a log P value of 4.6, which is favorable for tissue distribution (23). Log P, pKa, and percent protein binding values and drug transporter affinities of the analyzed ARVs are displayed in Table S1 in the supplemental material.

In conclusion, drug concentrations in different tissues vary among different species. Whereas data in NHPs agree with some data in humans, humanized mouse models are in concordance with other data in humans, depending on the tissues and individual drugs evaluated. These results suggest that drug exposure in tissues should be evaluated in preclinical models when considering scaling interventions to humans and that increased plasma concentrations do not always translate to tissue penetration, an important finding in view of proposed intensification strategies.

ACKNOWLEDGMENTS

This work was supported by the following funding sources: NIH R01AI111891 (to A.D.M.K.), NIH P30AI50410 (University of North Carolina at Chapel Hill Center for AIDS Research), NIH U01AI095031 (to A.D.M.K.), and P51OD011107 (California National Primate Research Center). This work was supported by shared resources through NIMH and NINDS by the following grants: U24MH100931 (Manhattan HIV Brain Bank), U24MH100930 (Texas Neuro AIDS Research Center), U24MH100929 (National Neurological AIDS Bank), and U24MH100928 (California NeuroAIDS Tissue Network).

A.S.D. is supported by the National Institute of General Medical Sciences, NIH, under award number T32GM086330.

We thank Howard Fox and Elizabeth Kulka of the National NeuroAIDS Tissue Consortium for providing the human tissue samples for brain, lymph node, and spleen in this study.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

FOOTNOTES

    • Received 26 August 2019.
    • Returned for modification 19 September 2019.
    • Accepted 8 October 2019.
    • Accepted manuscript posted online 14 October 2019.
  • Supplemental material is available online only.

  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Fletcher CV,
    2. Staskus K,
    3. Wietgrefe SW,
    4. Rothenberger M,
    5. Reilly C,
    6. Chipman JG,
    7. Beilman GJ,
    8. Khoruts A,
    9. Thorkelson A,
    10. Schmidt TE,
    11. Anderson J,
    12. Perkey K,
    13. Stevenson M,
    14. Perelson AS,
    15. Douek DC,
    16. Haase AT,
    17. Schacker TW
    . 2014. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 111:2307–2312. doi:10.1073/pnas.1318249111.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Huang Y,
    2. Hoque MT,
    3. Jenabian M-A,
    4. Vyboh K,
    5. Whyte S-K,
    6. Sheehan NL,
    7. Brassard P,
    8. Bélanger M,
    9. Chomont N,
    10. Fletcher CV,
    11. Routy J-P,
    12. Bendayan R
    . 2016. Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site. J Antimicrob Chemother 71:1954–1965. doi:10.1093/jac/dkw046.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Best BM,
    2. Koopmans PP,
    3. Letendre SL,
    4. Capparelli EV,
    5. Rossi SS,
    6. Clifford DB,
    7. Collier AC,
    8. Gelman BB,
    9. Mbeo G,
    10. McCutchan JA,
    11. Simpson DM,
    12. Haubrich R,
    13. Ellis R,
    14. Grant I
    , CHARTER Group. 2011. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother 66:354–357. doi:10.1093/jac/dkq434.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Akkina R
    . 2013. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 435:14–28. doi:10.1016/j.virol.2012.10.007.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Thompson CG,
    2. Fallon JK,
    3. Mathews M,
    4. Charlins P,
    5. Remling-Mulder L,
    6. Kovarova M,
    7. Adamson L,
    8. Srinivas N,
    9. Schauer A,
    10. Sykes C,
    11. Luciw P,
    12. Garcia JV,
    13. Akkina R,
    14. Smith PC,
    15. Kashuba A
    . 2017. Multimodal analysis of drug transporter expression in gastrointestinal tissue. AIDS 31:1669–1678. doi:10.1097/QAD.0000000000001554.
    OpenUrlCrossRef
  6. 6.↵
    1. Srinivas N,
    2. Rosen EP,
    3. Gilliland WM,
    4. Kovarova M,
    5. Remling-Mulder L,
    6. De La Cruz G,
    7. White N,
    8. Adamson L,
    9. Schauer AP,
    10. Sykes C,
    11. Luciw P,
    12. Garcia JV,
    13. Akkina R,
    14. Kashuba A
    . 2019. Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species. Xenobiotica 49:1192–1201. doi:10.1080/00498254.2018.1539278.
    OpenUrlCrossRef
  7. 7.↵
    1. Burgunder E,
    2. Fallon JK,
    3. White N,
    4. Schauer AP,
    5. Sykes C,
    6. Remling-Mulder L,
    7. Kovarova M,
    8. Adamson L,
    9. Luciw P,
    10. Garcia JV,
    11. Akkina R,
    12. Smith PC,
    13. Kashuba A
    . 2019. Antiretroviral drug concentrations in lymph nodes: a cross-species comparison of the effect of drug transporter expression, viral infection, and sex in humanized mice, nonhuman primates, and humans. J Pharmacol Exp Ther 370:360–368. doi:10.1124/jpet.119.259150.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Denton PW,
    2. Krisko JF,
    3. Powell DA,
    4. Mathias M,
    5. Kwak YT,
    6. Martinez-Torres F,
    7. Zou W,
    8. Payne DA,
    9. Estes JD,
    10. Garcia JV
    . 2010. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 5:e8829. doi:10.1371/journal.pone.0008829.
    OpenUrlCrossRef
  9. 9.↵
    1. Neff CP,
    2. Ndolo T,
    3. Tandon A,
    4. Habu Y,
    5. Akkina R
    . 2010. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 5:e15257. doi:10.1371/journal.pone.0015257.
    OpenUrlCrossRef
  10. 10.↵
    1. Veselinovic M,
    2. Yang K-H,
    3. LeCureux J,
    4. Sykes C,
    5. Remling-Mulder L,
    6. Kashuba ADM,
    7. Akkina R
    . 2014. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor tenofovir and entry inhibitor maraviroc in a humanized mouse model. Virology 464–465:253–263. doi:10.1016/j.virol.2014.07.008.
    OpenUrlCrossRef
  11. 11.↵
    1. Massud I,
    2. Martin A,
    3. Dinh C,
    4. Mitchell J,
    5. Jenkins L,
    6. Heneine W,
    7. Pau C-P,
    8. García-Lerma JG
    . 2015. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques. J Antimicrob Chemother 70:1473–1481. doi:10.1093/jac/dku556.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Shytaj IL,
    2. Norelli S,
    3. Chirullo B,
    4. Della Corte A,
    5. Collins M,
    6. Yalley-Ogunro J,
    7. Greenhouse J,
    8. Iraci N,
    9. Acosta EP,
    10. Barreca ML,
    11. Lewis MG,
    12. Savarino A
    . 2012. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 8:e1002774. doi:10.1371/journal.ppat.1002774.
    OpenUrlCrossRef
  13. 13.↵
    1. Cottrell ML,
    2. Yang KH,
    3. Prince HMA,
    4. Sykes C,
    5. White N,
    6. Malone S,
    7. Dellon ES,
    8. Madanick RD,
    9. Shaheen NJ,
    10. Hudgens MG,
    11. Wulff J,
    12. Patterson KB,
    13. Nelson JAE,
    14. Kashuba A
    . 2016. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis 214:55–64. doi:10.1093/infdis/jiw077.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Anderson PL,
    2. Kiser JJ,
    3. Gardner EM,
    4. Rower JE,
    5. Meditz A,
    6. Grant RM
    . 2011. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 66:240–250. doi:10.1093/jac/dkq447.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Pantaleo G,
    2. Graziosi C,
    3. Butini L,
    4. Pizzo PA,
    5. Schnittman SM,
    6. Kotler DP,
    7. Fauci AS
    . 1991. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A 88:9838–9842. doi:10.1073/pnas.88.21.9838.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Mattapallil JJ,
    2. Douek DC,
    3. Hill B,
    4. Nishimura Y,
    5. Martin M,
    6. Roederer M
    . 2005. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434:1093–1097. doi:10.1038/nature03501.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Lin JH
    . 1995. Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23:1008–1021.
    OpenUrlAbstract
  18. 18.↵
    1. Lin JH
    . 1998. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26:1202–1212.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Thompson CG,
    2. Bokhart MT,
    3. Sykes C,
    4. Adamson L,
    5. Fedoriw Y,
    6. Luciw PA,
    7. Muddiman DC,
    8. Kashuba ADM,
    9. Rosen EP
    . 2015. Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs. Antimicrob Agents Chemother 59:2944–2948. doi:10.1128/AAC.04952-14.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Mavigner M,
    2. Habib J,
    3. Deleage C,
    4. Rosen E,
    5. Mattingly C,
    6. Bricker K,
    7. Kashuba A,
    8. Amblard F,
    9. Schinazi RF,
    10. Jean S,
    11. Cohen J,
    12. McGary C,
    13. Paiardini M,
    14. Wood MP,
    15. Sodora DL,
    16. Silvestri G,
    17. Estes J,
    18. Chahroudi A
    . 2018. Simian immunodeficiency virus persistence in cellular and anatomic reservoirs in antiretroviral-suppressed infant rhesus macaques. J Virol 92:e00562-18. doi:10.1128/JVI.00562-18.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Thompson CG,
    2. Rosen EP,
    3. Prince HMA,
    4. White N,
    5. Sykes C,
    6. de la Cruz G,
    7. Mathews M,
    8. Deleage C,
    9. Estes JD,
    10. Charlins P,
    11. Mulder LR,
    12. Kovarova M,
    13. Adamson L,
    14. Arora S,
    15. Dellon ES,
    16. Peery AF,
    17. Shaheen NJ,
    18. Gay C,
    19. Muddiman DC,
    20. Akkina R,
    21. Garcia JV,
    22. Luciw P,
    23. Kashuba A
    . 2019. Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species. Sci Transl Med 11:eaap8758. doi:10.1126/scitranslmed.aap8758.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Alam C,
    2. Whyte-Allman S-K,
    3. Omeragic A,
    4. Bendayan R
    . 2016. Role and modulation of drug transporters in HIV-1 therapy. Adv Drug Deliv Rev 103:121–143. doi:10.1016/j.addr.2016.05.001.
    OpenUrlCrossRef
  23. 23.↵
    1. Testa B,
    2. Crivori P,
    3. Reist M,
    4. Carrupt P-A
    . 2000. The influence of lipophilicity on the pharmacokinetic behavior of drugs: concepts and examples. Perspect Drug Discov Des 19:179–211. doi:10.1023/A:1008741731244.
    OpenUrlCrossRef
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs
Aaron S. Devanathan, Jason R. Pirone, Ramesh Akkina, Leila Remling-Mulder, Paul Luciw, Lourdes Adamson, J. Victor Garcia, Martina Kovarova, Nicole R. White, Amanda P. Schauer, Kimberly Blake, Craig Sykes, Erin M. Burgunder, Nithya Srinivas, Elias P. Rosen, Angela D. M. Kashuba
Antimicrobial Agents and Chemotherapy Dec 2019, 64 (1) e01639-19; DOI: 10.1128/AAC.01639-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs
Aaron S. Devanathan, Jason R. Pirone, Ramesh Akkina, Leila Remling-Mulder, Paul Luciw, Lourdes Adamson, J. Victor Garcia, Martina Kovarova, Nicole R. White, Amanda P. Schauer, Kimberly Blake, Craig Sykes, Erin M. Burgunder, Nithya Srinivas, Elias P. Rosen, Angela D. M. Kashuba
Antimicrobial Agents and Chemotherapy Dec 2019, 64 (1) e01639-19; DOI: 10.1128/AAC.01639-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

HIV
antiretrovirals
pharmacokinetics
species differences
tissue reservoirs

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596